Seeking Alpha

Neurocrine Biosciences (NBIX) -2.8% AH after announcing a Phase II study for its NBI-98854 drug...

Neurocrine Biosciences (NBIX) -2.8% AH after announcing a Phase II study for its NBI-98854 drug for treating tardive dyskinesia failed to meet its primary endpoint, when a site featuring "inconsistent and incorrect application" of its assessment protocol was included. Without the site in question, the study showed a significant reduction in TD symptoms.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs